Objectives: Discrimination between infectious and noninfectious causes of acute respiratory failure is difficult in patients admitted to the ICU after a period of hospitalization. Using a novel biomarker test (SeptiCyte LAB), we aimed to distinguish between infection and inflammation in this population. Test results were categorized into four probability bands (higher bands indicating higher infection probability) and compared with the infection plausibility as rated by post hoc assessment using strict definitions. Of 467 included patients, 373 (80%) were treated for a suspected infection at admission. Infection plausibility was classified as ruled out, undetermined, or confirmed in 135 (29%), 135 (29%), and 197 (42%) patients, respectively. Test results correlated with infection plausibility (Spearman's rho 0.332; p < 0.001). After exclusion of undetermined cases, positive predictive values were 29%, 54%, and 76% for probability bands 2, 3, and 4, respectively, whereas the negative predictive value for band 1 was 76%. Diagnostic discrimination of SeptiCyte LAB and C-reactive protein was similar (p = 0.919). Conclusions: Among hospitalized patients admitted to the ICU with clinical uncertainty regarding the etiology of acute respiratory failure, the diagnostic value of SeptiCyte LAB was limited. (Crit Care Med 2018; 46:368-374) 
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For information regarding this article, E-mail: M.E.Brouwer-6@umcutrecht.nl ; Diana M. Verboom, MD 1, 2 ; Brendon P. Scicluna, PhD 3 ; Kirsten van de Groep, MD 1, 2 ; Jos F. Frencken, MD 1, 2 ; Davy Janssen 4 ; Rob Schuurman, PhD 4 the presence of systemic inflammation, most did not diagnose or rule out infection with sufficient rigor (1) (2) (3) (4) . Distinct protein biomarkers likely provide an (over)simplified representation of the host immune response to infection (2, 5) , which is very complex yet largely similar to that following major surgery, trauma, and various other diseases triggering systemic inflammation (6) . As a result, the use of single biomarkers may be predestined to yield only limited diagnostic value (2, 5) .
Recently, a novel diagnostic test (SeptiCyte LAB; Immunexpress, Seattle, WA) was developed which aims to provide a probability of infection based on the expression of a specific genomic fingerprint consisting of carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4), lysosomal-associated membrane protein 1 (LAMP1), phospholipase A2 group VII (PLA2G7), and placenta-specific 8-gene protein (PLAC8) (7) . The simultaneous analysis of RNA transcription by these four genes in peripheral blood potentially uses information that is contained in various unrelated pathways of the host response at the transcriptome level. This new technology was recently approved by the American Food and Drug Administration. In two technical validation studies, SeptiCyte LAB was highly specific for infection in selected groups of both adult and pediatric patients, including some subjects for whom presence or absence of infection was already self-evident at the time of testing (7, 8) . As a result, the precise clinical utility of the test for discriminating infectious and noninfectious causes of inflammation in the ICU remains unknown.
Patients for whom a diagnostic biomarker for infection is particularly relevant are those admitted to the ICU with acute respiratory failure (ARF) after a previous stay in hospital wards. They frequently suffer from prolonged ICU stays and high mortality (9), yet dyspnea in these patients is a very nonspecific symptom and its differential diagnosis is thus extensive, including congestive heart failure, pleural effusion, atelectasis, pulmonary embolus, acute respiratory distress syndrome, and-virtually always-infection. Early confirmation of infection allows timely initiation of antimicrobial therapy, whereas early rejection might prompt a comprehensive diagnostic workup for noninfectious causes of respiratory distress. Therefore, we aimed to determine the diagnostic and prognostic value of SeptiCyte LAB in hospitalized patients admitted to the ICU with ARF.
MATERIALS AND METHODS

Study Design
For this nested cohort analysis, we selected patients who were enrolled in the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, a prospective observational cohort study in the tertiary mixed ICUs of the University Medical Center Utrecht and the Academic Medical Center Amsterdam in the Netherlands (10) . Ethical approval for the study was provided by the Medical Ethics Committees of both hospitals, and an opt-out procedure to obtain consent from eligible patients was in place (protocol number 10-056).
Patients
Patients were included if they had been admitted to the ICU between January 2011 and December 2013 with ARF (evidenced by a need for mechanical ventilation within 24 hr of presentation) following prior hospital stay (on a general ward, coronary care unit, or medium care unit) of at least 48 hours. Furthermore, all patients had to have an early warning score greater than 5 (a clinical screening tool based on six cardinal vital signs [11] ) and/or presence of greater than and equal to two systemic inflammatory response syndrome criteria at ICU admission. Patients were excluded if they had another pertinent need for intubation, and ARF was evidently not caused by an infection (including, but not limited to, chronic respiratory insufficiency, primary cardiac arrest, and airway obstruction) or if a diagnosis of infection already had been established at the time of ICU admission (i.e., confirmed infections for which antimicrobial therapy had been started > 2 d prior to ICU admission) as the SeptiCyte LAB test was considered to offer little added value in clinical decision-making in such patients.
Reference Diagnosis
Infectious events were registered upon each occasion that antimicrobial therapy was initiated and subsequently adjudicated using detailed definitions derived from Center of Disease Control and International Sepsis Forum Consensus Conference criteria (10, 12, 13) . To this end, dedicated physicians not involved in patient care categorized infection plausibility as none, possible, probable, or definite, based on a comprehensive post hoc review of available clinical, microbiological, and radiologic data. Daily discussions between observers and the attending team served to reach consensus in case of any uncertainties. For use as reference test in the current analysis, we reclassified all plausibility ratings into the following categories: infection ruled out (patients with a post hoc likelihood rated none or patients who were not treated for infection), infection undetermined (patients with possible infection), or infection confirmed (patients with a post hoc likelihood rated probable or definite).
SeptiCyte LAB
Blood specimens were collected within 24 hours of ICU admission in all patients using 2.5 mL PAXgene Blood RNA Tubes (PreAnalytiX GmbH, Hombrechtikon, Switzerland). Samples were kept for a period of 2-72 hours at room temperature and subsequently stored at -20°C (for a maximum of 1 month) and finally stocked at -80°C until analysis. RNA was then isolated on a QIAcube workstation using a PAXgene blood miRNA kit (Qiagen, Venlo, the Netherlands). The concentration of total RNA per sample was assessed by Nanodrop spectrophotometry (Agilent, Amstelveen, the Netherlands) and had to be between 2 and 50 ng/uL to be eligible for further analysis.
SeptiCyte LAB tests were performed in 96-well microtiter amplification plates on an Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher Scientific, Carlsbad, CA). During each amplification run, three control samples were included. PCR results were initially quantified using ABI Sequence Detection Software version 1. LAB score was then calculated from the threshold cycle numbers (Ct values) measured per gene as follows: "SeptiCyte LAB score = (Ct PLA2G7 + Ct CEACAM4 ) -(Ct PLAC8 + Ct LAMP1 )." The resulting score was finally classified into four probability bands reflecting an increasing sepsis likelihood according to the manufacturer's specification; scores lesser than or equal to 3.1 represented band 1 and were categorized as "sepsis unlikely," whereas scores 3.1-4, 4-6, and greater than 6 represented bands 2, 3, and 4, respectively, and were categorized as "sepsis likely."
Statistical Analysis
We performed mainly descriptive analyses to determine the diagnostic value of SeptiCyte LAB as formal assessment of test characteristics was precluded due to the large proportion of patients in whom infection status remained inconclusive. However, some diagnostic measures were calculated, not taking into account these latter patients. Furthermore, we calculated the area under the receiver operating curve (AUROC) to compare the performance of SeptiCyte LAB with CRP, a biomarker commonly used in clinical practice. CRP was not measured at ICU admission in 115 (25%) cases; these values were replaced with estimates derived from multiple imputation (details can be found in Appendix I, Supplemental Digital Content 1, http://links.lww.com/CCM/C888) (14, 15) .
To assess the potential utility of SeptiCyte LAB for risk stratification of patients upon ICU admission, we studied the relation of test results with case fatality (after correction for disease severity). We constructed two prognostic models, using the Acute Physiology and Chronic Health Evaluation (APACHE) IV score either alone or combined with the SeptiCyte LAB score to predict 30-day mortality. We used generalized linear mixed models with a binomial distribution and logit link and added a random intercept to accommodate possible outcome differences between participating hospitals. Model evaluation was based on Akaike's information criterion (AIC) and the AUROC.
Differences between subgroups of patients were tested using the Wilcoxon Rank-Sum test or the Chi-square test, as appropriate. To test differences in patient characteristics associated with increasing SeptiCyte LAB scores, p values for trend were calculated using the Cochran-Armitage trend test for dichotomous variables, or one-way analysis of variance (ANOVA) for continuous variables. If ANOVA suggested a significant association, linear regression with the SeptiCyte probability band as group determinant was performed. All analyses were performed in SAS Enterprise 
RESULTS
Patients
Among 1399 hospitalized patients admitted to the ICU with ARF during the study period, 638 subjects were eligible for inclusion (Fig. 1) . Blood samples were unavailable in 157 of these, mostly because specimens had been used for prior studies within the MARS project. Fourteen other patients could not be evaluated due to technical issues during sample preparation or processing, leaving 467 subjects (73%) for final analysis. Compared with included patients, patients without samples for analysis had less congestive heart failure, more chronic cardiovascular insufficiency, and higher APACHE IV scores and ICU mortality (Appendix II, eTable 1, Supplemental Digital Content 1, http://links.lww.com/ CCM/C888).
Presence of Infection
Because of presumed infection, 359 of 467 included patients (77%) received antimicrobial therapy on day 1 in the ICU, and another 14 subjects (3%) started treatment on day 2. Among these, the post hoc plausibility of infection was rated none in 41 cases (11%). An additional 94 patients did not receive antimicrobial therapy during the first 2 days in the ICU, yielding a total of 135 subjects in whom infection was considered ruled out. The remaining 332 patients were classified as undetermined (n = 135) or infection confirmed (n = 197). Hence, in the total study population, the pretest probability of infection was 197/467 (42%). Of the patients in whom infection was undetermined or confirmed, the most commonly suspected sites of infection were respiratory tract infections (n = 228), abdominal infections (n = 52), and bloodstream infections (n = 36).
SeptiCyte LAB Results
In patients in whom infection was ruled out (n = 135), undetermined (n = 135), or confirmed (n = 197), median (interquartile range [IQR]) SeptiCyte LAB scores were 4.8 (3.7-6.1), 5.3 (3.9-6.4), and 6.5 (5.2-8.1), respectively ( Fig. 2) . Formal analysis yielded a significant correlation between test scores and the probability of infection (Spearman's rho 0.320; p < 0.001). However, Ct values for all four individual genes were largely overlapping (Appendix III, eFig. 1, Supplemental Digital Content 1, http://links.lww. com/CCM/C888). Table 1 shows the probability bands for infection at admission according to the SeptiCyte LAB score in relation to the reference diagnosis. Dichotomizing test results at band greater than or equal to 2 (as per manufacturer specification [7] ), concordance was observed in 189 of 197 patients (96%) with confirmed infection, yet in only 25 of 135 patients (18%) in whom infection was eventually ruled out. Using SeptiCyte LAB at this cut-off to select patients for antimicrobial treatment would have led to inappropriate prescriptions in 110 cases (of which only 38 were currently treated). After exclusion of undetermined cases, the positive predictive values for probability bands 2, 3, and 4 were 29%, 54%, and 76%, respectively, and the negative predictive value for probability band 1 was 76%.
Discrepancy Analysis
We observed eight discordant cases where the test suggested that infection could be safely ruled out, whereas infection was confirmed on post hoc assessment. Review of these false-negative cases revealed that these patients were older, had lower severity of illness upon presentation to the ICU, and more frequently had been previously admitted to the ICU than the 189 patients with true positive results ( Table 2) . Case descriptions for these patients are provided in Appendix IV (Supplemental Digital Content 1, http://links.lww.com/CCM/C888). In-depth analysis of the 110 patients with false-positive results revealed that they had similar age, higher severity of illness, more previous ICU admissions, and were more likely to have been clinically suspected of infection than their 25 true negative counterparts. In addition, we compared individual RNA transcripts in discrepant cases. Ct values differed significantly for the PLA2G7, CEACAM4, and (possibly) PLAC8 genes, but not for LAMP1, when comparing false positive to true negative results (Fig. 3A) . Similarly, there were significant differences in the median Ct values of PLAC8 and PLA2G7 when comparing false negative and true positive test results, but not for LAMP1 and CEACAM4 (Fig. 3B) .
Comparative Diagnostic Evaluation
To better assess the clinical utility of SeptiCyte LAB in the ARF population, we compared its diagnostic performance to CRP. In patients in whom infection was ruled out, undetermined, 
Prognostic Evaluation
Higher SeptiCyte LAB scores were associated with both greater disease severity upon ICU admission and increased mortality (Appendix V, eTable 2, Supplemental Digital Content 1, http://links.lww.com/CCM/ C888). However, a prognostic model that included both APACHE IV and SeptiCyte LAB scores was not superior in predicting 30-day mortality compared with a model using only the APACHE IV score (AUROC 0.737 vs 0.735; p = 0.724; AIC 498 vs 497).
DISCUSSION
In this study, we evaluated the clinical utility of SeptiCyte LAB to diagnose infection in patients admitted to the ICU because of ARF after a period of hospitalization. Infectious episodes were correctly identified by the test in 96% of the patients with confirmed infection. However, in patients in whom an infection was refuted, the test yielded a correct result in only 18% of patients. In fact, in this population, the test did not offer better diagnostic discrimination than the more commonly used biomarker CRP. In addition, SeptiCyte LAB did not improve prognostication when added to the APACHE IV score. Previous studies of SeptiCyte LAB reported very high discriminative power for infection (AUCs of 0.88 and 0.99) compared with what we observed (7, 8) . The major difference between those studies and ours concerns the study domain. Early validation studies have mostly used cohorts in which infectious and noninfectious patients could clearly be distinguished on clinical grounds. For instance, one study compared children after cardio-pulmonary bypass surgery to children with severe sepsis (8) . In another preliminary evaluation of SeptiCyte LAB (which included 23 subjects also enrolled in the current study), the test performed better in a cohort of highly selected patients (AUC 0.95; 95% CI, 0.91-1.00) than in a cohort representing a more real-life setting (AUC 0.85; 95% CI, 0.75-0.95) (7) . Furthermore, an assessment of its diagnostic performance across 39 publicly available datasets yielded highly variable findings, with reported AUCs ranging from 0.24 to 1 for individual datasets (16) . In search of a possible explanation for the lack of discriminative performance of SeptiCyte LAB in certain subgroups (some of which did not represent the intended use population of the test), it was noted that the expression of one of the four genes involved in calculating the SeptiCyte LAB score (CEACAM4) was down-regulated during sepsis in the discovery cohort, but not in other cohorts (16) . In our study, we observed only minimal differences in gene expression between infectious and noninfectious cases for all four genes, including CEACAM4 (Appendix III, eFig. 1, Supplemental Digital Content 1, http://links.lww.com/CCM/C888). We deliberately focused on a target population in which it was difficult to diagnose infections with certainty. Many patients had significant (acute) comorbidities, had stayed in the hospital for prolonged periods of time prior to ICU admission, and had previously been exposed to antimicrobials for (presumed) infections. To avoid selection, we enrolled consecutive patients. However, 171 of 638 eligible patients were excluded from analysis, mostly because they had a clinically apparent sepsis syndrome (due to confirmed infection) and their samples had already been used for other studies within the MARS project. These exclusions thus enriched our study cohort with infectious episodes that were more challenging to diagnose. Yet, we believe there is little value in using SeptiCyte LAB (or any other biomarker) in patients with clinically overt infection.
Although the probability of infection was prospectively adjudicated by trained observers based on available post hoc clinical, radiologic, and microbiological findings, some diagnostic misclassification will most likely have occurred (10) . For instance, infectious episodes for which treating physicians did not initiate antimicrobial therapy may have been erroneously classified as infection ruled out. It is important to stress that, in the presence of an imperfect reference test, the maximal discriminative performance (in terms of AUROC) that can be attained by a diagnostic test will be necessarily lower than 1. Thus, diagnostic misclassification may have reduced the apparent diagnostic utility of SeptiCyte LAB in our cohort. This merely emphasizes the difficulty of performing diagnostic studies in patients with infection, where a gold standard simply does not exist. However, it is unlikely that the lack of a robust reference diagnosis explains the observed differences in discriminative power of the test between our study and previous validation cohorts, nor the equipoise between SeptiCyte LAB and a more common host-response marker such as CRP in classifying infections (7) .
CONCLUSIONS
In our clinical evaluation of SeptiCyte LAB in patients presenting to the ICU with ARF after prior hospitalization for other acute diseases, the discriminative power of this new biomarker test was lower than previously reported in more selective validation cohorts. As SeptiCyte LAB scores are based on gene expression profiles, test results might vary between specific populations and/or settings. Therefore, more prospective studies are needed to determine the clinical utility of this novel test.
